A Phase 4 interventional study of Tamsulosin and Solifenacin in Lower Urinary Tract Symptoms, Overactive Bladder and Benign Prostatic Hyperplasia (BPH), sponsored by Astellas Pharma Taiwan, Inc.. Completed at 1 site in Taiwan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2016-03-22.
Sponsored by Astellas Pharma Taiwan, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · Astellas Pharma Inc.
Among the 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc, this one is the 38th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2007, is one of 15 in phase 4, and was the 61st registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →None of the 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc is open now. The open studies under Urinary Bladder, Overactive, anywhere →
Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 547 across the 49 interventional studies, 863 across the 17 observational. Of the 66 that completed or were terminated, 22 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astellas Pharma Taiwan, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Taiwan, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms in Taiwan.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
This study's enrollment of 52 is below the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Browse Urinary Bladder, Overactive studies →Astellas Pharma Taiwan, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Urinary Bladder, Overactive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lower Urinary Tract Symptoms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tamsulosin
Drug: Tamsulosin · Drug: Solifenacin
Oral
Also known as: Harnalidge® D
Oral
Also known as: Vesicare®
Change in International Prostate Symptoms Score (IPSS-(S)) from baseline to the end of treatment
Time frame: Baseline and end of treatment (up to 12 weeks)
Change in mean number of urgency episode per 24 hours from baseline to the end of treatment
Time frame: Baseline and end of treatment (up to 12 weeks)
Change in mean number of micturitions per 24 hours from baseline to the end of treatment
Time frame: Baseline and end of treatment (up to 12 weeks)
Change in Quality of life index (I-PSS-(L)) from baseline to the end of treatment
Time frame: Baseline and end of treatment (up to 12 weeks)
Change in maximum flow rate (Qmax) and voided volume determined by uroflowmetry from baseline to the end of treatment
Time frame: Baseline and end of treatment (up to 12 weeks)
Safety as assessed by adverse events
Time frame: Up to 12 weeks
Safety as assessed by postvoid residual volume (PVR)
Measured by bladder scan
Time frame: Up to 12 weeks
Safety as assessed by vital signs
Time frame: Up to 12 weeks
Safety as assessed by laboratory parameters
Time frame: Up to 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Sep 2007, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin